Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial by Provencio, Mariano, MD, Nadal, Ernest, MD, Insa, Amelia, MD, García-Campelo, María Rosario, MD, Casal-Rubio, Joaquín, MD, Dómine, Manuel, MD, Majem, Margarita, MD, Rodríguez-Abreu, Delvys, MD, Martínez-Martí, Alex, MD, De Castro Carpeño, Javier, MD, Cobo, Manuel, MD, López Vivanco, Guillermo, MD, Del Barco, Edel, MD, Bernabé Caro, Reyes, MD, Viñolas, Nuria, MD, Barneto Aranda, Isidoro, MD, Viteri, Santiago, MD, Pereira, Eva, MSc, Royuela, Ana, PhD, Casarrubios, Marta, MSc, Salas Antón, Clara, MD, Parra, Edwin R, PhD, Wistuba, Ignacio, MD, Calvo, Virginia, MD, Laza-Briviesca, Raquel, MSc, Romero, Atocha, PhD, Massuti, Bartomeu, MD, Cruz-Bermúdez, Alberto, PhD

Get full text

Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis by Antonia, Scott J, MD, Borghaei, Hossein, DO, Ramalingam, Suresh S, MD, Horn, Leora, MD, De Castro Carpeño, Javier, MD, Pluzanski, Adam, MD, Burgio, Marco A, MD, Garassino, Marina, MD, Chow, Laura Q M, MD, Gettinger, Scott, MD, Crinò, Lucio, Prof, Planchard, David, MD, Butts, Charles, MD, Drilon, Alexander, MD, Wojcik-Tomaszewska, Joanna, MD, Otterson, Gregory A, MD, Agrawal, Shruti, PhD, Li, Ang, PhD, Penrod, John R, PhD, Brahmer, Julie, MD

Get full text

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial by Fehrenbacher, Louis, Dr, Spira, Alexander, MD, Ballinger, Marcus, PhD, Kowanetz, Marcin, PhD, Vansteenkiste, Johan, Prof, Mazieres, Julien, Prof, Park, Keunchil, Prof, Smith, David, MD, Artal-Cortes, Angel, MD, Lewanski, Conrad, MD, Braiteh, Fadi, MD, Waterkamp, Daniel, MD, He, Pei, PhD, Zou, Wei, PhD, Chen, Daniel S, MD, Yi, Jing, PhD, Sandler, Alan, MD, Rittmeyer, Achim, MD

Get full text